GlassScriptPhysician profile
Karin P Bigman
NPI 1285690529
$2,503.54
in general payments reported to CMS, 2019-2025
48 companies · $24.02 in 2025
The $24.02 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $117 · 2021: $16.82 · 2022: $443 · 2023: $881 · 2024: $617 · 2025: $24.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $241.65 | 2019-2023 | |
| Celgene Corporation | $175.93 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Beigene USA, INC. | $142.89 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $133.79 | 2019-2024 | Erleada, Akeega, Balversa |
| Incyte Corporation | $119.67 | 2019-2024 | Jakafi |
| Merck Sharp & Dohme LLC | $114.97 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $110.73 | 2023-2024 | Imfinzi, Calquence, Enhertu |
| Eisai INC. | $99.29 | 2023-2024 | |
| Kite Pharma, INC. | $88.29 | 2022-2023 | |
| Amgen INC. | $85.55 | 2019-2023 | Lumakras |
| Taiho Oncology, INC. | $75.39 | 2019-2024 | |
| Pfizer INC. | $71.29 | 2019-2023 | |
| Abbvie INC. | $67.52 | 2023-2025 | Venclexta |
| Seagen INC. | $57.78 | 2019-2023 | Adcetris, Tivdak |
| Daiichi Sankyo INC. | $56.20 | 2019-2024 | Enhertu |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Bigman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.